Section Arrow
SLNO.NASDAQ
- Soleno Therapeutics
Quotes are at least 15-min delayed:2026/04/11 04:10 EDT
Regular Hours
Last
 52.63
+0.12 (+0.23%)
Day High 
52.69 
Prev. Close
52.51 
1-M High
52.69 
Volume 
3.57M 
Bid
52.3
Ask
52.7
Day Low
52.48 
Open
52.5 
1-M Low
29.43 
Market Cap 
2.72B 
Currency 美元 
P/E 134.49 
%Yield -- 
10-SMA 41.2 
20-SMA 37.2 
50-SMA 38.74 
52-W High 90.3199 
52-W Low 29.43 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
0.39/5.61
Enterprise Value
2.77B
Balance Sheet
Book Value Per Share
8.70
Cash Flow
Cash Flow Yield
0.02
Income Statement
Total Revenue
190.41M
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
CUECue Biopharma0.5019+0.209+71.36%-- 
QNCXQuince Therapeutics0.1363+0.0126+10.19%-- 
VRAXVirax Biolabs Group Limited0.1041-0.0308-22.83%-- 
ZNTLZentalis Pharmaceuticals6.61+2.19+49.55%-- 
IOVAIovance Biotherapeutics3.7-0.31-7.73%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulationof a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue. The company's reporting segment focused on the development and commercialization of its sole therapeutic product, VYKAT XR.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.